HilleVax $200 million IPO
The shares are listed on the Nasdaq Global Select Market
Davis Polk advised the joint book-running managers in connection with the upsized initial public offering of 11,765,000 shares of common stock of HilleVax, Inc. at $17.00 per share for total gross proceeds of approximately $200 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “HLVX.”
HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Dana Lueck-Mammen and Jacquiley Wong. The intellectual property and technology transactions team included partner David R. Bauer and associate Brette L. Trost. The tax team included counsel Tracy L. Matlock and associate Justin Corvino. Counsel Marcie A. Goldstein provided FINRA advice. Counsel Sijia Cai provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.